Announcements Trials
Browse Landscape

Phase

Phase 3 2Phase 2 1

Status

Completed 17Terminated 7Recruiting 5Active not recruiting 3Unknown 2Withdrawn 1

Sponsor Class

INDUSTRY 2OTHER 1

Study Type

Interventional 3

Sponsor

Cancer Type

NET 3Endocrine 3Gastrointestinal 1

Conditions

Breast Neoplasms 9Endometrial Neoplasms 4Carcinoma, Renal Cell 4Neuroendocrine Tumors 3Tuberous Sclerosis 2Recurrence 2Neoplasm Metastasis 2Kidney Neoplasms 2Thyroid cancer, Hurthle cell 1Thyroid Neoplasms 1Thyroid Diseases 1Solid Tumor 1Seizures 1Sarcoma 1Primary Non-metastatic Breast Cancer 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Myelodysplastic Syndromes 1Multiple Endocrine Neoplasia Type 1 1Liposarcoma 1Leukemia, Myeloid, Acute 1Leiomyosarcoma 1Gastro-enteropancreatic neuroendocrine tumor 1Endometrial Hyperplasia 1Clear-cell metastatic renal cell carcinoma 1Breast Neoplasms, Male 1Angiomyolipoma 1Advanced Solid Tumors 1Advanced Cancer 1

Interventions

lutetium Lu 177 dotatate 11Magnetic Resonance Spectroscopy 6Specimen Handling 5pembrolizumab 4cabozantinib 4Nivolumab 3Everolimus 3lenvatinib 2avelumab 2amino-acid, glucose, and electrolyte solution 2X-Rays 2Temozolomide 2Phantoms, Imaging 2Octreotide 2Lutetium-177 2Ipilimumab 23-aminopyridine-2-carboxaldehyde thiosemicarbazone 2177Lu-octreotide, DOTA(0)-Tyr(3)- 2toripalimab 1tislelizumab 1telotristat ethyl 1surufatinib 1peposertib 1pazopanib 1fludarabine phosphate 1fludarabine 1entrectinib 1atezolizumab 1Surgical Procedures, Operative 1Salts 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Active not recruiting × Neuroendocrine Tumors × Everolimus × Clear all
NCT03049189 2026-04-06

COMPETE

ITM Solucin GmbH

Phase 3 Active not recruiting
324 enrolled 15 charts
EndocrineNET

Neuroendocrine Tumors

NCT03950609 2026-03-19

Lenvatinib and Everolimus in Treating Patients With Advanced, Unresectable Carcinoid Tumors

M.D. Anderson Cancer Center

Phase 2 Active not recruiting
36 enrolled
EndocrineNET

Neuroendocrine Tumors, Multiple Endocrine Neoplasia Type 1

NCT04919226 2025-09-10

COMPOSE

ITM Solucin GmbH

Phase 3 Active not recruiting
259 enrolled
EndocrineGastrointestinalNET

Gastro-enteropancreatic neuroendocrine tumor, Neuroendocrine Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡